abexinostat

Known as: 2-benzofurancarboxamide, 3-((dimethylamino)methyl)-n-(2-(4-((hydroxyamino)carbonyl)phenoxy)ethyl)-, 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)-1-benzofuran-2-carboxamide, HDAC Inhibitor PCI-24781 
A broad-spectrum phenyl hydroxamic acid inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. Abexinostat inhibits several… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
0520132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Histone deacetylase (HDAC) inhibitor abexinostat is under investigation for the treatment of various cancers. Epigenetic changes… (More)
Is this relevant?
2016
2016
UNLABELLED : The epigenetic mechanisms promoting lineage-specific commitment of human skeletal (mesenchymal or stromal) stem… (More)
Is this relevant?
2015
2015
BACKGROUND It has been demonstrated that several inhibitors of histone deacetylase (HDAC) can enhance chemotherapy-induced… (More)
Is this relevant?
2015
2015
Background We determined the safety, pharmacokinetics, pharmacodynamics, and antitumour activity of abexinostat in B-cell… (More)
  • figure 1
  • table 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
EBV-related nasopharyngeal carcinomas (NPCs) still raise serious therapeutic problems. The therapeutic potential of the histone… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
PURPOSE Cancer stem cells (CSC) are the tumorigenic cell population that has been shown to sustain tumor growth and to resist… (More)
Is this relevant?
2013
2013
Abexinostat is a pan histone deacetylase inhibitor (HDACi) that demonstrates efficacy in malignancy treatment. Like other HDACi… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2013
2013
Abexinostat, an oral pan-histone deacetylase inhibitor (HDACi), was evaluated in patients with advanced solid tumours in two… (More)
Is this relevant?
2013
2013
In this study, we investigated the cytotoxic effects of a broad-spectrum histone deacetylase (HDAC) inhibitor, PCI-24781, alone… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2013
2013
A population pharmacokinetic/pharmacodynamic (PK/PD) model was developed to describe the thrombocytopenia (dose-limiting toxicity… (More)
  • figure 1
  • table II
  • table III
  • figure 3
  • figure 2
Is this relevant?